DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Patiromer
Patiromer
ACC.Org/Infographics ©2020 American College of Cardiology W20006
Pharmacology
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Patiromer for Treating Hyperkalaemia
Pharmacologic Treatment of Chronic Hyperkalemia in CKD KDIGO Gheun-Ho Kim, MD
205739Orig1s000
Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
Therapeutic Class Overview Electrolyte Depleters
HALF-YEAR REPORT 2019 Worldreginfo - F1b4840d-3Aaa-4093-82D3-3B7d6701d3b7
POTASSIUM BINDERS Lokelma (Sodium Zirconium Cyclosilicate), Veltassa (Patiromer)
Outcomes in End-Stage Renal Disease Patients on Hemodialysis Taking Patiromer for Hyperkalemia TH-PO779 Dinesh K
Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
Patiromer (VELTASSA) Drug Monograph
Patiromer and Sodium Zirconium Cyclosilicate
Therapeutic Class Overview Electrolyte Depleters
(Via PUBMED) #1 Hyperkalemia[TIAB] OR Hyperkalaemia[TIAB]
AKDC Prescription Formulary
Top View
New Product Evaluations - a Resource for Medicines Management
Clinical Practice Guidelines – Treatment of Acute Hyperkalaemia in Adults – July 2020 2
Anatomical Classification Guidelines V2018 EPHMRA ANATOMICAL
Patiromer Powder for Oral Suspension
Derbyshire Joint Area Prescribing Committee Annual Report April 2017
(SZC): Use in Adults with Chronic Hyperkalaemia 1) SUMMARY
Clinical Review Report for Sodium Zirconium Cyclosilicate (Lokelma) 2
Package Leaflet: Information for the Patient Veltassa 8.4 G Powder For
View Board for Each Center Before Full Inclusion and Exclusion Criteria Are Provided in Supplemen- Study Initiation
Kidney News | April 2016
New Treatment Options for Hyperkalemia in Patients with Chronic Kidney Disease
Study Protocol
Drug Crystal-Related Gastrointestinal Complications Involve Crystal-Induced Release of Neutrophil and Monocyte Extracellular Traps
Patiromer for Hyperkalaemia – First Line
Medication Coverage Policy
Patiromer Sorbitex Calcium Vifor Pharma Pty Ltd PM-2016‐02731‐1‐5 Final 11 September 2019
Fy 2020 Gdufa Science and Research Report
Guidelines for ATC Classification and DDD Assignment 2021
Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism
Patiromer (As Patiromer Sorbitex Calcium) 8.4G and 16.8G Powder for Oral Suspension (Veltassa®) Vifor Fresenius Medical Care Renal Pharma UK Ltd
Lokelma and Veltassa
Effect of Patiromer on Serum Potassium Level in Patients with Hyperkalemia and Diabetic Kidney Disease the AMETHYST-DN Randomized Clinical Trial
QRG for the Use of Sodium Zironconium Cyclosilicate Or Patiromer Calcium in the Management of Acute Hyperkalaemia During the COVID-19 Pandemic
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
SUOMEN LÄÄKETILASTO S LT FINNISH STATISTICS on MEDICINES FSM 8 Keskeisiä Lukuja Lääkkeiden Myynnistä Ja Lääkekorvauksista Vuonna 2018
Acute Management of Hyperkalemia
Potassium Exchangers
REAL-WORLD OUTCOMES of HYPERKALEMIA MANAGEMENT with PATIROMER in END-STAGE RENAL DISEASE PATIENTS UNDERGOING HEMODIALYSIS in the UNITED STATES Dinesh K
207078Orig1s000
Effect of Patiromer on Serum Potassium Level In
Office of Clinical Pharmacology Integrated Review
07/01/2019 P&T May 2019 Formulary Changes Notice